Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03206177 · OUTCOME

Median Overall Survival (Months)

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary · Source last updated 2024-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
through study completion, an average of 3 years

What was measured

Overall survival defined as time from study entry to death

Analysis population: Patients who received at least four cycles of study drug

Groups in this outcome

Paclitaxel/Carboplatin + Galunisertib

Galunisertib: Galunisertib 150mg po BID day 4-17 Paclitaxel: Paclitaxel 175 mg/m2 over 3 hours Carboplatin: IV day 1 Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Paclitaxel/Carboplatin + Galunisertib23

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Paclitaxel/Carboplatin + Galunisertib18.91Not reported10.81NAThe curve that represents the upper confidence limit never crosses below 0.5 and therefore an upper bound for the median value cannot be calculated.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The curve that represents the upper confidence limit never crosses below 0.5 and therefore an upper bound for the median value cannot be calculated.
        group Id
        OG000
        lower Limit
        10.81
        upper Limit
        NA
        value
        18.91
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Overall survival defined as time from study entry to death
dispersion Type
95% Confidence Interval
groups
  1. description
    Galunisertib: Galunisertib 150mg po BID day 4-17 Paclitaxel: Paclitaxel 175 mg/m2 over 3 hours Carboplatin: IV day 1 Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)
    id
    OG000
    title
    Paclitaxel/Carboplatin + Galunisertib
param Type
MEDIAN
population Description
Patients who received at least four cycles of study drug
reporting Status
POSTED
time Frame
through study completion, an average of 3 years
title
Median Overall Survival (Months)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice